Pfizer working capital

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

195.76×	195.76×	204.83×	196.04×	174.51×	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
27.15×	27.15×	30.45×	28.24×	22.84×
—	—	—	2.51×	−15.92×
—	—	—	221.77×	213.27×
0.81×	0.79×	0.78×	1.00×	1.32×
0.51×	0.51×	0.50×	0.53×	0.61×
1.34×	1.34×	0.86×	0.47×	—
1.07×	1.07×	0.89×	0.40×	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

PFIZER₹3,759.80

Pfizer Ltd.

· Pharma & Health

₹ CrorePeersGLAXO ABBOTINDIA POLYMED ONESOURCE RAINBOW KIMS JUBLPHARMA VIJAYA

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Inventory Days (DIO)	174.51	196.04	204.83	195.76	195.76
Receivable Days (DSO)	22.84	28.24	30.45	27.15	27.15
Payable Days (DPO)	-15.92	2.51	—	—	—
Cash Conversion Cycle (days)	213.27	221.77	—	—	—
Working Capital Turnover	1.32	1.00	0.78	0.79	0.81
Asset Turnover	0.61	0.53	0.50	0.51	0.51
Cash Conversion (CFO/Net Income)	—	0.47	0.86	1.34	1.34
CFO/EBITDA	—	0.40	0.89	1.07	1.07

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.